

July 29-31, 2025 | San Diego, CA



# TRP Targeted Radiopharmaceuticals Summit US

Transforming the Lives of Patients through Precision Radiopharmaceuticals

## Maximizing the Future of Radiopharmaceuticals Through Novel Targets, Next Generation Ligands & Translating Bench to Bedside Clinical Performance Through Quantitative Imaging & Robust Isotope Supply

50+ World-Class Speakers Including:



**Amreen Husain**  
Chief Medical Officer  
RayzeBio



**Goekben Koca**  
Chief Medical Officer  
Mariana Oncology



**David Hirsch**  
Chief Executive Officer  
Alpha-9 Oncology



**Phil Brandish**  
Chief Development Officer  
AI Proteins



**Haihong Jin**  
Chief Scientific Officer  
VitsGen Therapeutics



**Johannes Czernin**  
Professor  
UCLA



**Shona Whyte**  
Director, Search & Evaluation  
Novartis



**Kevin Roland**  
Vice President, CMC  
Abdera Therapeutics



**Jack Hoppin**  
Chief Executive Officer  
Ratio Therapeutics



**50+**  
Expert Speakers



**275+**  
Attendees



**3**  
Brand-New Tracks of Content

REGISTER  
BY JULY 28 &  
SAVE \$100

CONTENTS

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO


PARTNER  
WITH US

PARTNERS



REGISTER  
NOW

Proud to Partner With:



+1 617 455 4188

info@hansonwade.com

www.targeted-radiopharma-us.com

Targeted Radiopharmaceuticals





# Welcome to the 4<sup>th</sup> Targeted Radiopharmaceuticals Summit US

Radiopharmaceuticals are taking center stage in biopharma, and the race is truly on. **Sanofi's** collaborations with **Orano Med** and **AdvanCell** illustrates additional pharma buy-in, and household names like **Novartis** are further cementing their presence with **Ratio Tx**. There is no doubt - radiopharmaceuticals are shaping the future of medicine and are here to stay. The **4th Targeted Radiopharmaceuticals Summit US** is the largest, industry-dedicated forum tackling the most exciting opportunities and pressing challenges within this dynamic field!

Uncover the latest clinical developments shaping our understanding of optimal radiopharmaceutical dosing, clinical design and regulatory frameworks. Discover **novel targeting molecule engineering**, including miniproteins, peptides, small molecules, and more, to expand novel targets like **MSLN**, **CLDN18.2** and **HER-2**, while exploring commercial considerations for target selection.

The community will come together to share key translational insights to help **de-risk** your **first in-human** radiopharmaceutical trial and secure **isotope supply** from on the outset. Bringing together insights from the leading radiopharmaceutical minds across pharma, biotech, academia, and clinical practice - spanning **discovery**, **preclinical**, **clinical**, **CMC** and **supply chain** - this is your opportunity to network and learn from the experts.


Built with our radiopharmaceutical community leaders **Novartis**, **AstraZeneca**, **Bayer** and **Eli Lilly**, the **4th Targeted Radiopharmaceuticals Summit US** is gathering industry's key opinion leaders to delve into topics spanning the novel targeting mechanisms, regulations for alpha emitters, nuclear medicine clinical expertise, isotope supply and more!

4th Annual  
**TRP** Targeted Radiopharmaceuticals  
Summit US  
July 29-31, 2025 | San Diego, CA

## Attend the 4<sup>th</sup> TRP Summit US Summit to:



**Harnessing Cutting-Edge Engineering Techniques:** Pioneering novel radiopharmaceutical targeting molecules derived from **engineered antibodies, peptides, bi-specifics** and **mini proteins** with **Telix Pharmaceuticals**, **AI Proteins**, **OncoOne** and **VitsGen**



**Ensuring Successful Clinical Translation:** Employing **phase zero** and optimal first-in human design strategies with **AdvanCell**, **Alpha-9 Oncology** and **RayzeBio**, while leveraging real-world evidence in late-phase design with **UCLA**, **UCSF** and **Convergent Tx**



**Evaluating the Supply Chain and CMC Landscape:** Analyzing the current and future **dynamics of radiopharmaceutical supply chains**, and the **CMC** landscape, including **isotope availability**, **funding trends**, and **emerging technologies** with **William Blair** and **Abdera Therapeutics**



**Understanding the Radiopharmaceutical Regulatory Landscape:** Comparing diagnostics, theranostics and therapeutics, while harmonizing regulatory standards with **RadioPharm Theranostics** and **Fusion Pharmaceuticals**



**Attracting Continued Investment and Funding:** Understanding investor trends, focusing on, targeting moiety, platform technology, and payloads with **Novartis**, **William Blair**, **Telix Pharmaceuticals** and **Alpha-9 Oncology**

REGISTER  
BY JULY 28 &  
SAVE \$100

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW

2

+1 617 455 4188

@ info@hansonwade.com

www.targeted-radiopharma-us.com

Targeted Radiopharmaceuticals





# What's New for 2025?

## Brand New Content:

### Fundamentals of Radiopharmaceuticals Pre-Conference

**Focus Track:** Radiopharmaceuticals are a highly specialized modality with a nuanced set of unique challenges and opportunities. The focus day will prime your end-to-end radiopharmaceutical understandings ahead of the main conference days

**Maximising the Radiopharmaceuticals Talent Pool:** As the field grows, explore how to preserve, recruit and keep your talent as well as encourage and nurture new talent in the field: including pharma and academic involvement

**Exploring Commercialization Feasibility, Reimbursement Management for Radiopharmaceuticals:** Discussing how to engage with community clinics and optimize patient referrals



“ The close collaboration between industry and clinicians. The representation by all various functions of industry, and a well thought out schedule ”

POINT Biopharma

## New C-Suite Speakers:



**Amreen Husain**  
Chief Medical Officer  
RayzeBio



**Colin Hayward**  
Chief Medical Officer  
Z-Alpha



**David Hirsch**  
Chief Executive Officer  
Alpha-9 Oncology



**Richard Messmann**  
Chief Medical Officer  
Convergent Tx

## New Funding & Investment Experts:



**Akshay Chellappa**  
Vice President,  
Global Business Development  
Telix  
Pharmaceuticals



**Shona Whyte**  
Director, Search  
& Evaluation  
Novartis



**Max Smock**  
Analyst  
William Blair

## Your KOL Clinicians:



**Johannes Czernin**  
Professor  
UCLA



**Munir Ghesani**  
Chief Medical Officer  
United  
Theranostics



**Jeremie Calais**  
Associate Professor  
UCLA




**Thomas Hope**  
Professor  
University of California, San Francisco



**Erik Mittra**  
Professor  
Oregon Health & Science University

## New Speaking Companies for 2025:



REGISTER  
BY JULY 28 &  
SAVE \$100

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW



# World Class 2025 Speakers - C-Suite Biopharma

4th Annual  
**TRP** Targeted Radiopharmaceuticals  
Summit US  
July 29-31, 2025 | San Diego, CA

REGISTER  
BY JULY 28 &  
SAVE \$100



**Alison Armour**  
Chief Medical Officer &  
Founder  
**Curadh MTR**



**Amreen Husain**  
Chief Medical Officer  
**RayzeBio**



**Anna Karmann**  
Chief Medical Officer  
**AdvanCell**



**Chris Adams**  
Chief Executive Officer  
**Andarix  
Pharmaceuticals**



**Colin Hayward**  
Chief Medical Officer  
**Z-Alpha**



**Daniel Stevens**  
Chief Medical Officer  
**Blue Earth  
Therapeutics**



**David Hirsch**  
Chief Executive Officer  
**Alpha-9 Oncology**



**Dirk Pleimes**  
Chief Medical Officer &  
Chief Executive Officer  
**Pentixapharm**



**Dylan Stoy**  
Director of Therapeutic  
Strategy  
**PSI CRO**




**Goekben Koca**  
Chief Medical Officer  
**Mariana Oncology**



**Haihong Jin**  
Chief Scientific Officer  
**VitsGen Therapeutics**



**Jack Hoppin**  
Chief Executive Officer  
**Ratio Therapeutics**



**Kamran Ali**  
Chief Technology Officer  
& Co-Founder  
**Eigen Therapeutics**



**Keene Wei**  
Chief Executive Officer  
**VitsGen**



**Kawa Chiu**  
Chief Technical Officer  
**Abdera Therapeutics**



**Jean Cho**  
Chief Executive Officer  
**Trevaxx**



**Manfred Rudgier**  
Chief Executive Officer  
**Ariceum**



**Mary C Hames**  
Chief Executive Officer  
**BioLogic Pharma  
Solutions**



**Munir Ghesani**  
Chief Medical Officer  
**United Theranostics**



**Phil Brandish**  
Chief Development  
Officer  
**AI Proteins**



**Randolf Kerschbaumer**  
Chief Executive Officer  
& Founder  
**OncoOne**



**Richard Messmann**  
Chief Medical Officer  
**Convergent Tx**



**Xueming Qian**  
Founder & Chief  
Executive Officer  
**Transcenta**

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW

4

+1 617 455 4188

@ info@hansonwade.com

www.targeted-radiopharma-us.com

Targeted Radiopharmaceuticals





# World Class 2025 Speakers - Biotech Leaders

4th Annual **TRP** Targeted Radiopharmaceuticals Summit US

July 29-31, 2025 | San Diego, CA

REGISTER  
BY JULY 28 &  
SAVE \$100

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW



**Adeela Kamal**  
Executive Vice President,  
Head of Research &  
Development  
**Actinium  
Pharmaceuticals**



**Alessandro Mascioni**  
Director, Targeting  
Technologies  
**Telix Pharmaceuticals**



**Alyssa Vito**  
Senior Director Clinical  
Development  
**Alpha-9 Oncology**



**Ashley Mishoe**  
Vice President,  
Regulatory Affairs &  
Quality Assurance  
**PharmaLogic**



**Charles Vriamont**  
Scientific Business  
Development Director  
**Trasis**



**David Bailey**  
Business Development  
Manager, Isotopes  
**SHINE Technologies**



**Donna Supko**  
Vice President,  
Regulatory Affairs  
**Radiopharm**



**Guido Wuerth**  
Head Corporate  
Development,  
Radiopharma, Affibody AB  
**Affibody**



**Hadis Westin**  
Scientific Marketing  
Director  
**Ridgeview Instruments**



**Jake Morris**  
Commercial Manager  
**Beacon by Hanson  
Wade**



**James Bowman**  
Director of Protein  
Engineering  
**AI Proteins**



**Jeremy Paull**  
Chief Scientific &  
Regulatory Officer  
**Starpharma**



**Kevin Machel**  
Product Manager  
Radionuclides & Devices  
**ITM**



**Kevin Roland**  
Vice President, CMC  
**Abdera Therapeutics**



**Luis Rivera**  
Executive Vice  
President, RTQA  
President  
**Mirion Medical**



**Mike Wardach**  
Vice President,  
Regulatory Affairs  
**Z-Alpha**



**Shaemus Gleasson**  
Senior Vice President  
**Clarity**



**Sherin Al-Safadi**  
Vice President, Medical  
Affairs  
**Radiopharm  
Theranostics**



**Weiliang (Timo) Xu**  
Associate Director of  
Business Development  
**PepLib**



+1 617 455 4188

@ info@hansonwade.com



www.targeted-radiopharma-us.com



Targeted Radiopharmaceuticals





# World Class 2025 Speakers - Pharma Leaders

4th Annual **TRP** Targeted Radiopharmaceuticals Summit US  
July 29-31, 2025 | San Diego, CA



**Ammar Ahmed Chaudhry**  
Global Clinical Head,  
Radiology & Nuclear  
Medicine  
**AstraZeneca**



**Ankur Nagaraja**  
Senior Clinical Program  
Leader  
**Novartis**



**A. Omer Nawaz**  
Vice President, Head of  
Radiation Science and  
Molecular Imaging  
**Fusion Pharmaceuticals | AstraZeneca**



**Gary Chia**  
Director, Radioligand  
Therapy Strategy  
**Novartis**



**Minnie Mildwoff**  
Global Therapeutic Area  
Lead  
**Novartis**



**Sudhakar Chintharlapalli**  
Vice President, Head of  
Biology & Translational  
**RayzeBio**



**Suzanne Gaudet**  
Director  
**Novartis**

# World Class 2025 Speakers - Academia & Clinicians




**David Mankoff**  
Professor & Vice-  
Chair for Research,  
Department of Radiology  
**University of Pennsylvania**



**Erik Mittra**  
Professor  
**Oregon Health & Science University**



**Michael Evans**  
Professor  
**University of Californian, San Francisco**



**Jeremie Calais**  
Associate Professor  
**UCLA**



**Johannes Czernin**  
Professor  
**UCLA**



**Thomas Hope**  
Professor  
**University of California, San Francisco**

**REGISTER  
BY JULY 28 &  
SAVE \$100**

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



**REGISTER  
NOW**

# World Class 2025 Speakers - Investment, Funding & Business Leaders




4th Annual Targeted Radiopharmaceuticals Summit US

July 29-31, 2025 | San Diego, CA

REGISTER  
BY JULY 28 &  
SAVE \$100



**Akshay Chellappa**  
Vice President, Global  
Business Development  
**Telix Pharmaceuticals**



**Alexandra Ramsey**  
Equity Research  
Associate  
**William Blair**



**Andy Hsieh**  
Biotech Equity Research  
Analyst  
**William Blair**



**Max Smock**  
Analyst  
**William Blair**



**Shona Whyte**  
Director, Search &  
Evaluation  
**Novartis**



**Stephen Mitchener**  
Chief Business Officer  
**Alpha-9 Oncology**

“ I always enjoy attending the TRP conferences/summits - they are so well-organized, cover great content and the latest trends in the market and are the perfect size to allow us to network and have meaningful conversations and discussions with industry leaders, partners and clients ”

**AtomVie Global Radiopharma**

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS




REGISTER  
NOW



# Agenda at a Glance

REGISTER  
BY JULY 28 &  
SAVE \$100

Pre-Conference Day Tuesday, July 29			Conference Day One Wednesday, July 30			Conference Day Two Thursday, July 31		
<div>Workshop A</div> <div>Harnessing Patient-Centric Phase Zero Trials to Accelerate Speed to Clinic</div>	<div>OR</div> <div>Workshop D</div> <div>Assessing the Current &amp; Future Funding Environment for Radiopharmaceuticals to Guide Optimal Company Strategy</div>	<div>Fundamentals of Radiopharmaceuticals Focus Day</div> <div></div>	The Radiopharmaceutical Renaissance: Landscape Analysis & Clinical Updates			Exploring Commercial Directions for Radiopharmaceuticals & Considerations for Company Differentiation		
		<div>Harnessing Radiation for Precision Medicine: Introducing Radiopharmaceuticals</div>	Sharing Data for Real World Evidence Trial of Extended Use of Lu-117 Vipivotide Tetraxetan & the FLEX Trial on Flexible Dosing Schedules			Obtaining Winning Industry Partnerships to Advance Radiopharmaceutical Development		
		Morning Break & Speed Networking			Morning Break & Speed Networking			
Lunch Break & Networking			Discovery & Preclinical	Translational & Early-Stage Clinical	Supply Chain & Late-Stage Clinical	Discovery & Preclinical	Translational & Early-Stage Clinical	Supply Chain & Late-Stage Clinical
<div>Workshop B</div> <div>Peptides, Mini Proteins &amp; More: Delving into Challenges &amp; Opportunities for Amino Acid Based Targeting Moieties</div>	<div>OR</div> <div>Workshop E</div> <div>Tackling Actinium Impurities: Impurity Measurement, Manufacturing Challenges, Regulatory Collaboration, &amp; Waste Management</div>	<div>Exploring Drug Design to Formulation Choices for Commercially Viable Radiopharmaceuticals</div>	Unlocking Novel Radiopharmaceutical Targets & Targeting Strategies to Address Unmet Medical Need	Delivering Translational Success Through Optimal Preclinical Insights & Forward-Thinking Radiopharmaceutical Design	Strengthening Radiopharmaceutical CMC & Supply Chain through Novel Technologies & Regulatory Understandings	Mining for Gold: Uncovering Novel Radiopharmaceutical Targets for Blockbuster Drugs While Leveraging Novel Targeting Technologies	Lessons Learned from Progressing in the Clinic: Gearing up Your Clinical Trial	Optimizing Quality Control & Streamlining Radiopharmaceutical Supply Processes
			Afternoon Break & Networking			Morning Break & Speed Networking		
<div>Workshop C</div> <div>Assessing Antibodies for Radiopharmaceuticals &amp; Pre-targeting Strategies to Determine Success</div>	<div>OR</div> <div>Workshop F</div> <div>Evaluating Astatine-211 to Outline Distinct Radiolabeling Opportunities &amp; Optimal Decay Properties</div>	<div>Navigating Clinical &amp; Commercial Considerations to Guide Radiopharmaceutical Strategy</div>	Mining for Gold: Uncovering Novel Radiopharmaceutical Targets for Blockbuster Drugs	Uncovering First in Human & Early Clinical Data to Determine Novel Radiopharmaceutical Efficacy	Uncovering Key Clinical Learnings to Streamline Late-Stage Development	Engineering Approaches for Novel Radiopharmaceutical Delivery Innovations	Maximizing Dosimetry to Streamline Development	Ensuring Patient & Environmental Safety in Approved Therapies & Late-Stage Company Evolution
			Navigating Current Radiopharmaceutical Supply, Production & Building Talent Across the Field			Navigating the Regulatory Environment for Radiopharmaceuticals to Streamline Development		
End of Pre-Conference Day			End of Conference Day One			End of Conference Day Two		

- WELCOME
- WHAT'S NEW FOR 2025?
- SPEAKERS
- AGENDA AT A GLANCE
- PRE-CONFERENCE WORKSHOP DAY
- CONFERENCE DAY ONE
- CONFERENCE DAY TWO
- PARTNER WITH US
- PARTNERS



REGISTER  
NOW



# Pre-Conference Day | Tuesday, July 29

REGISTER  
BY JULY 28 &  
SAVE \$100

Workshop A		OR	Workshop D	Fundamentals of Radiopharmaceuticals Focus Day	
Using Patient-Centric Phase Zero Trials for Radiopharmaceutical Clinical Development			Assessing the Current & Future Funding Environment for Radiopharmaceuticals to Guide Optimal Company Strategy	Are you entering the field of radiopharmaceuticals? Whether you're a cross-industry drug development expert or new into the space, radiopharmaceuticals are a highly specialized modality with a nuanced set of unique challenges and opportunities. R&D drug hunter or clinician, our focus day will prime your end-to-end radiopharmaceutical understandings ahead of the main conference days, so you can make the most out of the cutting-edge focused content.	
<p><b>8.30</b> Serving as a bridge between preclinical and clinical development, <b>phase zero</b> studies can de-risk drug development by unlocking crucial pharmacokinetic and biodistribution data to optimize radiopharmaceutical drug candidates. Patient-centricity is at the core of phase zero studies and ethical considerations must be front and center in decision-making.</p> <p>Join this discussion-based workshop to gain insights on:</p> <ul style="list-style-type: none"><li>Uncovering variations in compassionate use across countries like <b>South Africa</b>, <b>Australia</b>, <b>Germany</b>, and <b>India</b>, each with unique purposes and ethical considerations</li><li>Ensuring ethical practices in diagnostics trials and patient involvement, advocating against unnecessary patient risk</li><li>Guiding the design of Phase 1 trials by providing insights into optimal dosing, scheduling, and safety considerations</li></ul> <p><b>Anna Karmann</b>, Chief Medical Officer, <b>AdvanCell</b></p> <p><b>Alyssa Vito</b>, Senior Director, Clinical Development, <b>Alpha-9 Oncology</b></p> <p><b>Sudhakar Chintharlapalli</b>, Vice President, Head of Biology &amp; Translational, <b>RayzeBio</b></p>			<p><b>8.30</b> The past year has seen a wealth of high-stake radiopharmaceutical M&amp;As and investments, but what are the <b>drivers of investor interest</b>, and will these trends continue? Assessing how the growing market and high returns potential could unlock support for smaller biotech while identifying potential challenges.</p> <p>Hear from the funding experts themselves on:</p> <ul style="list-style-type: none"><li>Digging down on what the investors are interested in from targeting moiety, platform technology to payload</li><li>Learning from industry stories to understand what it takes for a high-stakes investment</li><li>Understanding what <b>enhances radiopharmaceuticals commercial viability</b> to attract more investment</li><li>Exploring how to position and distinguish your technology's platform capabilities</li></ul> <p><b>Andy Hsieh</b>, Biotech Equity Research Analyst, <b>William Blair</b></p> <p><b>Alexandra Ramsey</b>, Equity Research Associate, <b>William Blair</b></p> <p><b>Shona Whyte</b>, Director, Search &amp; Evaluation, <b>Novartis</b></p> <p><b>Stephen Mitchener</b>, Chief Business Officer, <b>Alpha-9 Oncology</b></p>	<p><b>Harnessing Radiation for Precision Medicine: Introducing Radiopharmaceuticals Developmental Pathways</b></p> <p><b>8.30</b> <b>Revealing the Lutathera &amp; Pluvicto Stories from Bench to Bedside to Illustrate Prime Radiopharmaceutical Drug Development</b></p> <ul style="list-style-type: none"><li>Exploring chemical structures, medicinal chemistry and delivery mechanisms</li><li>Understanding key steps for successful translation and early clinical design</li><li>Assembling the clinical workforce for the path to commercialization</li></ul> <p><b>Richard Messmann</b>, Chief Medical Officer, <b>Convergent Tx</b></p> <p><b>9.00</b> <b>Outlining Radiopharmaceutical Diagnostics vs Therapeutics &amp; the Path to Blended Theranostics</b></p> <ul style="list-style-type: none"><li>Comparing diagnostic vs therapeutic landscapes and key nuances</li><li>Understanding opportunities in theranostic development</li></ul> <p><b>Ammar Ahmed Chaudhry</b>, Global Clinical Head, Radiology &amp; Nuclear Medicine, <b>AstraZeneca</b></p>	

## CONTENTS

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW

“ I liked the close collaboration between industry and clinicians. The representation by all various functions of industry, and a well thought out schedule ”  
**Eli Lilly**

10.30 Morning Break & Networking

**Workshop B**

**Peptides, Mini Proteins & More: Delving into Challenges & Opportunities for Amino Acid Based Targeting Moieties**

**11.00** As the radiopharmaceuticals field diversifies, we see more companies using a range of targeting molecules. There are distinct opportunities and challenges for using smaller targeting formats based on **circulation time, tumor retention, stability and kidney retention**. It's important to consider these properties when designing optimal radiopharmaceutical drugs.

Join this interactive deep dive to:

- Explore challenges in integral membrane target identification and mining for peptides and mini proteins
- Assess modifications to avoid kidney toxicities
- Understand novel chelator innovations to explore how to alter pharmacokinetics and biodistribution
- Addressing biological half-life and blending with payload

**Chris Adams**, Chief Executive Officer, **VitsGen**  
**Keene Wei**, Chief Executive Officer, **VitsGen Therapeutics**  
**Guido Wuerth**, Head Corporate Development, Radiopharma, **Affibody AB**  
**Phil Brandish**, Chief Development Officer, **AI Proteins**

**Workshop E**

**Addressing Actinium Impurities: Measuring Impurities, Manufacturing Risks, Working With Regulators & Managing Waste**

**11.00** <sup>225</sup>Ac is a promising radionuclide used for targeted alpha therapies. However, the production methods bring impurities. The long half-life of impurities raises **regulatory questions** around its safe use in the clinic. There are ongoing efforts to determine impurity level standards as well as waste licensing and disposal for optimal use of Actinium in the clinic.

Delve into sessions and discussions around:

- Using alpha spectrometry and other methods to determine impurity
- Sharing interactions with investigators to understand regulations
- Discussing licensing challenges for clinical use of <sup>225</sup>Ac with <sup>227</sup>Ac impurity
- Looking at alternative production methods
- Exploring what the future looks like for actinium in the clinic

**Manfred Rudgier**, Chief Executive Officer, **Ariceum**

**9.30 Panel Discussion: Commentary on Past & Future Developmental Pathways & Radiopharmaceutical Strategies**

- Delving into the radiopharma landscape and technical development pathways
  - Sharing experiences
- Richard Messmann**, Chief Medical Officer, **Convergent Tx**  
**Ammar Ahmed Chaudhry**, Global Clinical Head, Radiology & Nuclear Medicine, **AstraZeneca**

**10.00 Preclinical Techniques for Radiopharmaceuticals: The Gift of Dosimetry From Animal to Human**

- Understanding biophysical characterization and pharmacokinetic understandings
  - Using *in-vitro* assays in radiopharma
  - Understanding important terminologies when using dosimetry
- Suzanne Gaudet**, Director, **Novartis**

**Exploring Drug Design to Formulation Choices for Commercially Viable Radiopharmaceuticals**

**11.30 Exploring Radiopharmaceutical CMC Processes & Supply Chain Considerations to Guide Development**

- Understanding radiochemistry and CMC processes
  - Exploring opportunities for downstream optimization
  - Navigating challenging supply chains
- Shaemus Gleasson**, Senior Vice President, **Clarity**

**12.00 Designing a Radiopharmaceutical Clinical Trial: Key Considerations from the Start**

- Outlining the network of clinical experts who are involved from nuclear medical physicians to medical oncologists
  - Key differences in a radiopharma trial
  - Radiation safety considerations
- Sherin Al-Safadi**, Vice President, Medical Affairs, **Radiopharm Theranostics**

REGISTER  
BY JULY 28 &  
SAVE \$100

CONTENTS

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW



# Pre-Conference Day | Tuesday, July 29

REGISTER  
BY JULY 28 &  
SAVE \$100

## CONTENTS

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW

Nice balance of commercial, science and clinical  
RayzeBio

### 1.00 Lunch Break & Networking

#### Workshop C

OR

#### Workshop F

##### Assessing Antibodies for Radiopharmaceuticals & Pre-targeting Strategies to Determine Success

**2.00** Antibody conjugates have made blockbuster drugs in the ADC world and show promise to the radiopharmaceuticals field. While there are a large range of targets that can be addressed by antibodies, challenges in **radiolabeling and biological half-life remain**. Pre-targeting strategies may help unlock targeting specificity while matching biological half-life.

Join this interactive workshop to:

- Discuss Zevalin and Bexxar, previous antibody-based drugs, their efficacy and wider contextual and commercial factors
- Sharing novel prosthetic click-linker technologies
- Outlining radiolabeling strategies
- Exploring how to best match biological half-life with isotope half life
- Sharing pre-targeting strategies

**Dirk Pleimes**, Chief Medical Officer & Chief Scientific Officer, **Pentixapharm**

**Xueming Qian**, Founder & Chief Executive Officer, **Transcenta**

**Randolf Kerschbaumer**, Chief Executive Officer & Founder, **OncoOne**

##### Evaluating Astatine-211 to Outline Distinct Radiolabeling Opportunities & Optimal Decay Properties

**2.00** Astatine-211 offers significant advantages for smaller organic molecules due to its similarity to iodine in chemistry, eliminating the need for a chelator. This makes it easier to attach to drug-like molecules without altering their ability to bind to targets, unlike metal-based conjugates that often face challenges with chelator incorporation. While the supply of astatine is theoretically unlimited, niche cyclotron technologies affect availability.

Join this workshop for the opportunity to:

- Explore 211At decay properties to overcome toxicities
- Investigating potential of astatine development to industry-sponsored clinical trials
- Unlocking 211At conjugation chemistry and assessing prime biological targeting vectors, strategies and targets

**Colin Hayward**, Chief Medical Officer, **Z-Alpha**

**Mike Wardach**, Vice President, Regulatory Affairs, **Z-Alpha**

**David Mankoff**, Professor & Vice-Chair for Research, Department of Radiology, **University of Pennsylvania**

#### 12.30 Hearing Patient Stories to Put the Field in Perspective

- Hearing how approved treatments have changed the lives of patients
- Advocating patient-centricity in clinical design
- Inspiring addressing more unmet medical need

**Munir Ghesani**, Chief Medical Officer, **United Theranostics**

#### 2.30 Question & Answer Session with Radiopharmaceutical Pioneers to Elevate your Industry Understandings

Join our open session to ask your burning questions to the industry leaders ahead of the main conference to equip your team with expert knowledge ahead of the main conference.

Join this session to ask exactly what you want to know on topics like:

- **R&D and Preclinical**: novel target choices, targeting molecules, linkers, chelators, preclinical dosimetry and more
- **CMC and Regulatory**: isotope properties, differences in supply chain, logistics networks, CMC innovations, regulatory considerations and more
- **Clinical Development**: clinical trial design, working with sites, working with clinical stakeholders, patient centric approaches and more

**Munir Ghesani**, Chief Medical Officer, **United Theranostics**

**Justin Martin**, Director, Project Delivery Hematology/Oncology, Clinical Research Group, **PPD, a part of Thermo Fisher Scientific**

**Sherin Al-Safadi**, Vice President, Medical Affairs, **RadioPharm Theranostics**

**Shaemus Gleasson**, Senior Vice President, **Clarity**

**Ammar Ahmed Chaudhry**, Global Clinical Head, Radiology & Nuclear Medicine, **AstraZeneca**

**Suzanne Gaudet**, Director, **Novartis**

### 4.00 End of Pre-Conference Day



7.30 Morning Check-in & Light Breakfast



**Kawa Chiu**  
Chief Technical Officer  
Abdera Therapeutics

8.20 Chair's Opening Remarks

## The Radiopharmaceutical Renaissance: Landscape Analysis & Clinical Updates



**Jack Hoppin**  
Chief Executive Officer  
Ratio Therapeutics

8.30 Radiopharmaceutical Recap: Landscape Updates, Major Milestones & Trends for the Year(s) Ahead

- Sharing how the radiopharmaceuticals field is rapidly advancing, with growing clinical data shaping our understanding of pharmacokinetics, efficacy, and safety
- Examining where we stand and where we are heading across the landscape of therapeutic and diagnostic platforms
- Exploring radiation dosimetry, regulatory considerations, and manufacturing—highlighting key learnings and emerging challenges



**Jeremie Calais**  
Associate Professor  
UCLA

9.00 Illuminating a Future Beyond VISION 6x6 to Optimize Fixed Dosing Schedule

- Understanding whether we can do better than the approved fixed dosing schedule of Lu177-PSMA-617 for mCPRC patients: 7.4 Gbq per cycle, 6-week time interval between each cycle, up to 6 cycles max
- Reviewing literature and early findings from the UCLA IITs FLEX MRT NCT06216249 and RE-LuPSMA NCT06288113
- Exploring future considerations for optimal dosing



**Dylan Stoy**  
Director of Therapeutic Strategy  
PSI CRO

9.30 The State of Radiopharmaceuticals: Growth, Challenges & What's Ahead

- Explore early benefits, challenges, and driving forces behind radiopharma; learn how the industry has evolved, including current challenges and strategies for optimizing research.
- Understand how research infrastructure must scale to meet growing demand.
- Gain insights into future trends and how the industry can prepare for the next 5 years of innovation.

10.00 Panel Discussion: Exploring How Real-World Evidence Can Impact Design of Future RLT Trials

- Using real-world clinical outcomes to provide insights into patient populations, treatment efficacy and long-term safety
- Enhancing trial design through optimal patient selection, dosing strategies and endpoints
- Guiding potential personalized treatment strategies

### Moderator



**Kawa Chiu**  
Chief Technical Officer  
Abdera Therapeutics



**Thomas Hope**  
Professor  
University of California, San Francisco



**Jeremie Calais**  
Associate Professor  
UCLA



**Richard Messmann**  
Chief Medical Officer  
Convergent Tx



**Goekben Koca**  
Chief Medical Officer  
Mariana Oncology



10.30 Speed Networking & Refreshments

A prime opportunity to make the most of in-person networking and forge new connections with an expanding community of experts in the radiopharmaceutical field. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.

REGISTER  
BY JULY 28 &  
SAVE \$100

CONTENTS

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW



# Conference Day One | Wednesday, July 30

REGISTER BY JULY 28 & SAVE \$100

CONTENTS

WELCOME

WHAT'S NEW FOR 2025?

SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE WORKSHOP DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PARTNERS

REGISTER NOW

Discovery & Preclinical	Translational & Early-Stage Clinical	Supply Chain & Late-Stage Clinical
<p><b>Moving Beyond PSMA: Unlocking Novel Radiopharmaceutical Targets to Address Unmet Medical Need</b></p> <p><b>Chair: Adeela Kamal</b>, Executive Vice President, Head of Research &amp; Development, <b>Actinium Pharmaceuticals</b></p>	<p><b>Delivering Translational Success Through Optimal Preclinical Insights &amp; Forward-Thinking Radiopharmaceutical Design</b></p> <p><b>Chair: Sudhakar Chintharlapalli</b>, Vice President, Head of Biology &amp; Translational, <b>RayzeBio</b></p>	<p><b>Strengthening Radiopharmaceutical CMC &amp; Supply Chain through Novel Technologies &amp; Regulatory Understandings</b></p> <p><b>Chair: ITM</b></p>
<p><b>11.30 New Targets &amp; Chemical Approaches to Maximize the Therapeutic Index for Targeted Radiotherapies</b></p> <ul style="list-style-type: none"><li>Addressing approaches to exploit tumor specific antigens for targeted radiotherapy</li><li>Exploring new drug delivery mechanisms to increase tumor absorbed dose of radiopharmaceuticals while minimally altering pharmacokinetic profile</li></ul> <p><b>Michael Evans</b>, Professor, <b>University of Californian, San Francisco</b></p>	<p><b>11.30 Panel Discussion: Streamlining your Radiopharmaceutical Preclinical Package: Working With the Regulators</b></p> <ul style="list-style-type: none"><li>Understanding what's needed and what's not needed for a radiopharmaceutical preclinical package</li><li>Hear interactions with regulatory perspective</li><li>Biodistribution, preclinical dosimetry and more</li></ul> <p><b>Chris Adams</b>, Chief Executive Officer, <b>Andarix Pharmaceuticals</b></p> <p><b>Alyssa Vito</b>, Senior Director Clinical Development, <b>Alpha-9 Oncology</b></p> <p><b>Jeremy Paull</b>, Chief Scientific &amp; Regulatory Officer, <b>Starpharma</b></p> <p><b>Minnie Mildwoff</b>, Global Therapeutic Area Lead, <b>Novartis</b></p> <p><b>Hadis Westin</b>, Scientific Marketing Director, <b>Ridgeview Instruments</b></p>	<p><b>11.30 Panel Discussion: Understanding Regulations for Radiopharmaceutical Manufacturing &amp; Supply</b></p> <ul style="list-style-type: none"><li>Sharing interaction from working with regulators</li><li>Updates on regulatory interactions changes</li><li>Streamlining development</li></ul> <p><b>Kevin Roland</b>, Vice President, CMC, <b>Abdera Therapeutics</b></p> <p><b>Shaemus Gleasson</b>, Executive Vice President, <b>Clarity</b></p>
<p><b>12.00 Peptide Radioligand Development via PepLib's Advanced Peptide Discovery Platform</b></p> <ul style="list-style-type: none"><li>Introduction to PepLib's advanced peptide discovery platform and peptide radioligand pipelines</li><li>Case studies on our radioligand development targeting FAP, GPC3, and DLL3</li><li>Presentation of human IIT test results demonstrating the potency of our peptide radioligands</li></ul> <p><b>Weiliang (Timo) Xu</b>, Associate Director of Business Development, <b>PepLib</b></p>	<p><b>12.00 Session Reserved For:</b></p> <div> <b>LANTHEUS™</b></div>	<p><b>12.00 Built to Last: Creating a Quality-Driven, Collaborative CDMO Platform for Radiopharmaceutical Success</b></p> <ul style="list-style-type: none"><li>Comparing the regulatory frameworks of 21 CFR Part 211 and Part 212, emphasizing the key differences in compliance for radiopharmaceuticals</li><li>Harmonizing drug sponsor and CDMO quality system expectations for PET diagnostics and therapeutics</li><li>Leveraging CDMO regulatory experience to expedite sponsor submissions</li><li>Exploring the relationship between quality, regulatory, and CMC for optimal drug development.</li></ul> <p><b>Ashley Mishoe</b>, Vice President, Regulatory Affairs and Quality Assurance, <b>PharmaLogic</b></p>

# Conference Day One | Wednesday, July 30

REGISTER  
BY JULY 28 &  
SAVE \$100

**12.30 Building a Transformative Actinium-225 Portfolio for Next-Generation Precision Oncology**

- Targeting the untapped: validation of novel tumor-specific targets for Actinium-225 radiotherapeutics
- Bridging preclinical to clinical: translational studies to optimize efficacy and patient selection
- Addressing high unmet need: Leveraging alpha-emitters to overcome resistance mechanisms

**Adeela Kamal**, Executive Vice President, Head of Research & Development, **Actinium Pharmaceuticals**

**12.30 Increasing R&D Productivity with Clinical Development Excellence**

- Exploring global early-stage and late-stage development strategies
- Navigating patient selection and enrichment with imaging biomarkers; theranostic pair development
- Using biodistribution imaging and dosimetry while considering Ph1 study designs and dose optimization

**Anna Karmann**, Chief Medical Officer, **AdvanCell**

**12.30 Emerging Technologies for Radiopharmaceutical Production: End-To-End Solutions to Overcome New Radionuclides Challenges**

- Outlining the novel radionuclides landscape
- Exploring novel methods to enhance production efficiency, scalability, and environmental sustainability
- Sharing thoughts on future production perspectives

**Kevin Roland**, Vice President, CMC, **Abdera Therapeutics**



1.00 Lunch Break & Networking

**Discovery & Preclinical**

**Mining for Gold: Uncovering Novel Radiopharmaceutical Targets for Blockbuster Drugs**

**2.00 [At-211] Parthanatine: Bringing Alphas to Tumor DNA Using a PARP-Targeted Therapeutic Radiopharmaceutical for Novel Indications**

- Outlining At-211 labelled PARP-inhibitor analogs to target a binding site located on DNA
- Subcellular targeting to tumor DNA yield high potency alpha RPT
- Preclinical data support efficacy and tolerable toxicity in challenging disease such as neuroblastoma and ovarian cancer

**David Mankoff**, Professor & Vice-Chair for Research, Department of Radiology, **University of Pennsylvania**

**2.30 Analyzing the TRP Boom & Contextualizing a Growing Landscape**

- Exploring trends and updates from preclinical and clinical TRP developments
- Reviewing key highlights for TRP innovation and development in 2025
- Visualizing the evolution of the TRP development landscape, with perspective and insights on how far the space has come and where its headed

**Jake Morris**, Commercial Manager, **Beacon by Hanson Wade**

**Translational & Early-Stage Clinical**

**Uncovering First in Human & Early Clinical Data to Determine Novel Radiopharmaceutical Efficacy**

**2.00 Early Clinical & Program Updates**

- Outlining early clinical updates
- Exploring trial design and successes

**Manfred Rudgier**, Chief Executive Officer, **Ariceum**

**2.30 Session Reserved for:**



**Supply Chain & Late-Stage Clinical**

**Uncovering Key Clinical Learnings to Streamline Late-Stage Development**

**2.00 Sharing Clinical Perspectives to Optimize Industry Collaborations**

- Illuminating Clinical Perspectives to Optimize Industry Collaborations
- Understanding the clinical and patient perspective on industry trials
- Discussing key challenges and opportunities for improvement

**Erik Mittra**, Professor, **Oregon Health & Science University**

**2.30 SHINE's Scalable, U.S.-Made n.c.a. Lu-177 Shaping the Future of Radiopharma**

- Supply Chain Reinvented: How Ilumira's domestic, integrated model offers unmatched reliability and independence from non-U.S. sourced Yb-176
- Built to Scale: Patented, environmentally responsible production methods that scale with your clinical and commercial needs
- Customer-First Flexibility: Responsive partnerships built for innovation

**David Bailey**, Business Development Manager, Isotopes, **SHINE Technologies**

CONTENTS

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW



# Conference Day One | Wednesday, July 30

**2.45 Roundtables- Using Artificial Intelligence for In-Silico Radiopharmaceutical Drug Design to De-Risk Your Molecule**

- Exploring screening through in-silico models
- Understanding what data it can bring
- Maximizing understandings for novel radiopharmaceuticals

**3.00 Addressing Unmet Medical Need Through Novel Radiopharmaceutical CLDN18.2**

- Exploring development to address gastric cancer
- Preclinical radioimmunoconjugate data

**Xueming Qian**, Founder, Chairman & Chief Executive Officer, Transcenta Holding

**2.40 Roundtables - Designing First in Human – Clinical Design Considerations**

- Knowing what data to collect and how to interpret it
- Understanding how the dosimetry correlate to actual traditional
- toxicity markers, and efficacy readouts

**3.00 Novel Routes of Administration & Localized Therapy – Expanding the Use of Radiopharmaceuticals**

- Challenges and opportunities for locally delivered therapy
- Locally delivered precision radiopharmaceuticals
- Case study: Addressing unmet medical need in bladder cancer

**Dirk Pleimes**, Chief Medical Officer & Chief Scientific Officer, Pentixapharm

**2.45 Revolutionizing Radiopharmaceuticals Quality Control: How Trasis' QC1® and Sterinow®- the State-of-the-Art Automated Sterility Testing Technology – Deliver Together a Fully Integrated, Regulation-Ready Solution**

- The current QC landscape in radiopharmaceuticals and evolving market needs
- QC1®: Your lab-in-a-box — one sample, one click, one report — a fully automated quality control platform
- Sterinow®: The first and only fully automated, cassette-based sterility testing technology

**Charles Vriamont**, Scientific Business Development Director, Trasis

**3.00 Understanding How Many Patients Can Benefit from PSMA Targeted Theranostics**

- Presenting an analysis of the growth potential of PSMA targeted theranostics
- Discussing roadblocks towards growth
- Exploring opportunities and solutions to maximize adoption


**Johannes Czernin**, Professor, UCLA



**3.30 Afternoon Break & Poster Session**

This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of radiopharmaceutical experts eager to hear the latest drug delivery innovations, you will have the opportunity to display a poster presenting your own research. Don't miss out on the chance to connect, learn, and present.


## Navigating Current Radiopharmaceutical Supply, Production & Building Talent Across the Field



**Max Smock**  
Analyst  
**William Blair**

**4.00 Supply Chain State of the Union: Understanding the Current Manufacturing Environment for Radiopharmaceuticals**

- Discussing the need for in-house manufacturing and the current and future roles of CDMOs in the radiopharma supply chain
- Exploring funding trends for companies developing radiopharmaceuticals and CDMOs supporting this sector
- Outlining current isotope availability, identifying supply bottlenecks, and projecting future isotope availability



**Kevin Machel**  
Product Manager  
Radionuclides & Devices  
**ITM**

**4.30 Building a Sustainable & Scalable Actinium-225 Supply Chain for Global Applications**

- Advancing closed-loop production systems to minimize waste and environmental impact
- Scaling Ac-225 output efficiently through proton irradiation of Ra-226
- Building a resilient, decentralized supply chain to support global radiopharmaceutical needs

REGISTER BY JULY 28 & SAVE \$100

CONTENTS

WELCOME

WHAT'S NEW FOR 2025?

SPEAKERS

AGENDA AT A GLANCE


PRE-CONFERENCE WORKSHOP DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PARTNERS



REGISTER NOW

# Conference Day One | Wednesday, July 30

5.00 **Panel Discussion: Maximizing the Talent Pool for Radiopharmaceuticals to Accelerate Drug Development**

- Discussing how to preserve, recruit and keep your talent
- Identifying key bottlenecks from CMC to clinical personnel
- Exploring how to encourage and nurture new talent in the field: including pharma and academic involvement

Moderator




**Kawa Chiu**  
Chief Technical Officer  
Abdera Therapeutics



**Shaemus Gleasson**  
Executive Vice President  
Clarity



**Sherin Al-Safadi**  
Vice President, Medical Affairs  
Radiopharm Theranostics



**Gary Chia**  
Director, Radioligand Therapy Strategy  
Novartis



**Kawa Chiu**  
Chief Technical Officer  
Abdera Therapeutics

5.30 **End of Conference Day One**

“ I enjoyed the panel discussion and the presentation to show the isotope market, production in the future, as well as the updated data from novel radiopharmaceuticals ”

Alpha-9 Oncology

REGISTER  
BY JULY 28 &  
SAVE \$100

CONTENTS

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW



# Conference Day Two | Thursday, July 31

REGISTER  
BY JULY 28 &  
SAVE \$100

## CONTENTS

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS

REGISTER  
NOW



7.30 Morning Check-in & Light Breakfast



**Amir Golan**

Vice President, Radioligand  
Therapy Platform  
**Novartis**

8.20 Chair's Opening Remarks

## Exploring Commercial Directions for Radiopharmaceuticals & Considerations for Company Differentiation

### 8.30 Panel Discussion: Obtaining Winning Industry Partnerships to Advance Radiopharmaceutical Development

- Hearing from the experts on how to secure funding and industry partnerships
- Understanding how the process began and how to build relationships



**Akshay Chellappa**

Vice President, Global Business Development  
**Telix Pharmaceuticals**



**Shona Whyte**

Director, Search & Evaluation  
**Novartis**



**Stephen Mitchener**

Chief Business Officer  
**Alpha-9 Oncology**



**Goekben Koca**

Chief Medical Officer  
**Mariana Oncology**

### 9.00 The Mariana Oncology Story - Advancing the Next Generation of Precision Radioligand Therapies

- Story from conception to acquisition
- Innovative Precision RLTs expanding in solid tumor indications of high unmet need
- Showing first preclinical data



**Mary C Hames**

Chief Executive Officer  
**BioLogic Pharma  
Solutions**

### 9.30 The Fractional Medical Affairs Advantage: Increasing Efficiencies & Reducing Risk in the Radiopharmaceutical Industry

- Past, Present, & Future of Medical Affairs
- De-risking medical support during uncertainty in drug development & approval
- Securing full-team support without full team impact on resources

### 10.00 Panel Discussion: Commercialization Feasibility, Reimbursement Management for Radiopharmaceutical & Engaging with Community Clinics

- Increasing the number of centers capable of administering radiopharmaceuticals
- Getting more physicians comfortable with referring patients to nuclear medicine or radiation oncology
- Managing the growing ecosystem of intermediaries and service providers



**Amir Golan**

Vice President, Radioligand Therapy Platform  
**Novartis**



**Munir Ghesani**

Chief Medical Officer  
**United Theranostics**



10.30 Morning Break & Refreshments

# Conference Day Two | Thursday, July 31

Discovery & Preclinical	Translational & Early-Stage Clinical	Supply Chain & Late-Stage Clinical
<div>Expanding Horizons with Novel Targeting Moieties to Optimize Radiopharmaceutical Development</div> <div>Chair: Jean Cho, Chief Executive Officer, Trevaxx</div>	<div>Lessons Learned from Progressing in the Clinic: Gearing up Your Clinical Trial</div> <div>Chair: Kamran Ali, Chief Technology Officer &amp; Co-Founder, Eigen Therapeutics</div>	<div>Optimizing &amp; Streamlining Radiopharmaceutical Supply Processes to Accelerate Development</div>
<div>11.30 Pioneering Precision Theragnostics Through Engineered Antibody Fragments</div> <div><ul style="list-style-type: none"><li>Exploring strategies for engineering small biologics for use as radioligand therapy</li><li>Emphasizing how to mitigate off target uptake of the toxic payload</li></ul></div> <div>Alessandro Mascioni, Director, Targeting Technologies, Telix Pharmaceuticals</div>	<div>11.30 Harnessing Affibody Technology for Targeting and Treating HER2-Expressing Tumors</div> <div><ul style="list-style-type: none"><li>Affibody journey: from ABY-025, a HER2 directed PET tracer to ABY-271 HER2 targeting radioligand therapy</li><li>Enhancing ABY-271 with Albumod technology and making strategic choices: chelator and radioisotope in ABY-271</li><li>Designing first-in-human phase 1/2 clinical study based on ABY-025/ preclinical ABY-271 insights</li></ul></div> <div>Guido Wuerth, Head Corporate Development, Radiopharma, Affibody AB</div>	<div>11.30 Panel Discussion: Identifying Delays in Clinical Research to Streamline Development</div> <div><ul style="list-style-type: none"><li>Industry-clinic collaborations</li><li>Forward planning to avoid delays</li><li>Accelerating development among nuclear medicine teams</li></ul></div> <div>Richard Messmann, Chief Medical Officer, Convergent Therapeutics</div> <div>Ankur Nagaraja, Senior Clinical Program Leader, Novartis</div> <div>Amreen Husain, Chief Medical Officer, RayzeBio</div> <div>Erik Mittra, Professor, Oregon Health &amp; Science University</div>
<div>12.00 Roundtable Discussion: A New Wave: Unlocking Novel Targeting Strategies</div> <div><ul style="list-style-type: none"><li>Discussing drug design elements</li><li>Understanding challenges and opportunities with each targeting molecule</li></ul></div>	<div>12.00 A Connected Future: Enabling the Deployment of the Next Generation of a Precision Diagnostic &amp; Therapeutic Radiopharmaceuticals</div> <div><ul style="list-style-type: none"><li>An introduction to Mirion - A global leader in radiation safety solutions, with proven track record of supporting leading organizations in the fight against cancer</li><li>A proven portfolio - Mirion is already supporting members across the entire radiopharmaceutical value chain through a proven portfolio of trusted brands with unmatched breadth that is continuing to expand</li><li>A future for growth - By leveraging an ecosystem of hardware and software, and partnering with leading radiopharmaceutical companies, Mirion sees the potential to co-develop solutions to accelerate time to market and expand sites of care.</li></ul></div> <div>Luis Rivera, Executive Vice President, RTQA President, Mirion Medical</div>	<div>12.00 Innovation Spotlight- Exploring Alternative Actinium Production Methods to Overcome Regulatory Hurdles</div> <div><ul style="list-style-type: none"><li>Exploring innovations in production technologies for actinium</li><li>Understanding how this could streamline supply and remove impurity issues</li></ul></div>

REGISTER BY JULY 28 & SAVE \$100

CONTENTS

WELCOME

WHAT'S NEW FOR 2025?

SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE WORKSHOP DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PARTNERS

➔

REGISTER NOW



# Conference Day Two | Thursday, July 31

<p><b>12.30 Uncovering Pre-targeted Radioimmunotherapy for Novel Radiopharmaceutical Targets</b></p> <ul style="list-style-type: none"><li>• Sharing early preclinical therapeutic data</li><li>• Discussing compassionate use studies for speed to clinic</li><li>• Addressing unmet medical need through new targets including, oxMIF, MSLN, HER2, and Fra</li></ul> <p><b>Randolf Kerschbaumer</b>, Chief Executive Officer &amp; Founder, OncoOne</p>	<p><b>12.30 Using Radiation Dosimetry to Accelerate Clinical Development Decision Making: Early go/no go Decisions for Novel RLTs</b></p> <ul style="list-style-type: none"><li>• Learning from a case study in dosimetry</li><li>• Understanding how to achieve the best dat</li></ul> <p><b>Daniel Stevens</b>, Chief Medical Officer, <b>Blue Earth Therapeutics</b></p>	<p><b>12.30 Roundtables: Exploring the Future of Radiopharmaceutical Supply Distribution Networks</b></p> <ul style="list-style-type: none"><li>• Addressing challenges in production, storage, and distribution by leveraging advanced technologies and logistics to ensure timely delivery</li><li>• Outlining centralized and distributed networks and exploring the future for the field</li></ul>
<div><div><div></div><div></div></div><div>1.00 Lunch Break &amp; Networking</div></div>		
Discovery & Preclinical	Translational & Early-Stage Clinical	Supply Chain & Late-Stage Clinical
<p><b>Engineering Approaches for Novel Radiopharmaceutical Delivery Innovations</b></p> <p><b>2.00 Delivering Better Medicines Created Rapidly Through de novo Protein Design</b></p> <ul style="list-style-type: none"><li>• Creating 45 amino acid miniproteins using generative artificial intelligence</li><li>• Engineering mini proteins to bind targets with sub nanomolar affinities, and contain site-specific conjugation handles</li><li>• Small size of miniproteins enables rapid distribution and clearance</li></ul> <p><b>James Bowman</b>, Director of Protein Engineering, <b>AI Proteins</b></p> <p><b>2.30 21st Century Medicinal Chemistry Applied to RLT: Methodologies</b></p> <ul style="list-style-type: none"><li>• Reviewing VitsGen’s methodologies in applying AI modeling, phage display and computer aided design/medicinal chemistry design</li><li>• Using approaches to get BiC/FiC peptide based RLT molecules</li><li>• Outlining why peptide-based molecules are well-suited to the criteria for targeted radiopharmaceuticals</li></ul> <p><b>Haihong Jin</b>, Chief Scientific Officer, <b>VitsGen</b></p>	<p><b>2.00 Addressing Challenges in Radiopharmaceutical Dosimetry with FNIH’s Precision Dosimetry Imaging Biomarker Project</b></p> <ul style="list-style-type: none"><li>• Outlining current challenges in dosimetry use</li><li>• Sharing FNIH project and objectives to improve dosimetry</li></ul> <p><b>A. Omer Nawaz</b>, Vice President, Head of Radiation Science and Molecular Imaging, <b>Fusion Pharmaceuticals   AstraZeneca</b></p> <p><b>2.30 Panel Discussion- A Path Towards Defined Absorbed Dose Limits – What Does the Future Hold?</b></p> <ul style="list-style-type: none"><li>• Assembling the field to interrogate the data and determine standards</li><li>• Understanding how to engage with the regulators to reach a unified goal</li><li>• Individualized dosimetry</li></ul> <p><b>Daniel Stevens</b>, Chief Medical Officer, <b>Blue Earth Therapeutics</b></p> <p><b>A. Omer Nawaz</b>, Vice President, Head of Radiation Science and Molecular Imaging, <b>Fusion Pharmaceuticals   AstraZeneca</b></p>	<p><b>Ensuring Patient &amp; Environmental Safety in Approved Therapies &amp; Late-Stage Company Evolution</b></p> <p><b>2.00 Optimizing Clinical Design to Ensure Patient Safety in Radiopharmaceutical Development</b></p> <ul style="list-style-type: none"><li>• Implementing radiopharmaceuticals clinical lessons learned to streamline development</li><li>• Exploring commercialization considerations</li></ul> <p><b>Alison Armour</b>, Chief Medical Officer &amp; Founder, <b>Curadh MTR</b></p> <p><b>2.30 Roundtable Discussion: Maximizing Patient Recruitment by Streamlining Relationships</b></p> <ul style="list-style-type: none"><li>• Leveraging relationships with investigators</li><li>• Building your network of nuclear medicine physicians, medical oncologists and clinicians</li><li>• Sharing success stories</li></ul>
<div><div><div></div><div></div></div><div>3.30 Afternoon Break &amp; Networking</div></div>		

REGISTER BY JULY 28 & SAVE \$100

CONTENTS

WELCOME

WHAT’S NEW FOR 2025?

SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE WORKSHOP DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PARTNERS

REGISTER NOW

REGISTER BY JULY 28 & SAVE \$100

CONTENTS

WELCOME

WHAT'S NEW FOR 2025?

SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE WORKSHOP DAY

CONFERENCE DAY ONE





CONFERENCE DAY TWO

PARTNER WITH US

PARTNERS

→ REGISTER NOW

## Navigating the Regulatory Environment for Radiopharmaceuticals to Streamline Development

 <div><b>Donna Supko</b> Vice President, Regulatory Affairs <b>Radiopharm Theranostics</b></div>	<b>3.30</b>	<b>Regulatory Perspectives for Radiopharmaceuticals from Diagnostics, Theranostics &amp; Therapeutics</b> <ul style="list-style-type: none"><li>• Exploring key regulatory considerations for the development and marketing authorization of radiopharmaceuticals</li><li>• Touching on product type and target label claims, with a focus on the US regulatory landscape</li><li>• Uncovering future perspectives and initiatives for radiopharmaceutical regulatory affairs</li></ul>
<hr/>		
<b>4.00</b>	<b>Panel Discussion: Promoting Regulatory Harmonization for Radiopharmaceutical Clinical Research</b> <ul style="list-style-type: none"><li>• Discussing EMA's concept paper and FDA's project optimus</li><li>• Exploring how the field can harmonize regulations to streamline development</li></ul>	
 <div><b>Donna Supko</b> Vice President, Regulatory Affairs <b>Radiopharm Theranostics</b></div>	 <div><b>Mike Wardach</b> Vice President - Regulatory Affairs <b>Z-Alpha</b></div>	
<hr/>		
 <div><b>Amir Golan</b> Vice President, Radioligand Therapy Platform <b>Novartis</b></div>	<b>4.30</b>	<b>Chair's Closing Remarks</b>
<hr/>		
	<b>4.40</b>	<b>End of Conference</b>

▮▮ Talks were multidimensional and addressed science concepts along with insights on emerging pipeline activities ▮▮

**Bayer**



# Proud to Partner With

4th Annual **TRP** Targeted Radiopharmaceuticals Summit US  
July 29-31, 2025 | San Diego, CA



## PSI - Lead Partner

PSI is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI's global reach supports clinical trials across multiple countries and continents and specializes in the planning and execution of global pivotal registration clinical trials. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors.

[www.psi-cro.com](http://www.psi-cro.com)



## BioLogic Pharma Solutions - Expertise Partner

BioLogic Pharma Solutions is a one-of-a-kind medical affairs consulting group specializing in Fractional Medical Affairs to support pharmaceutical and biotech companies. With deep expertise in nuclear medicine and radiopharmaceuticals, we help bring radioisotopes to market while optimizing clinical trial execution, physician engagement, and medical communications. Our tailored, results-driven approach accelerates success in a complex biopharma landscape. Partner with us to navigate innovation and drive impact in medical affairs.

[www.biologicpharmasolutions.com](http://www.biologicpharmasolutions.com)



## ITM - Expertise Partner

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

[www.itm-radiopharma.com](http://www.itm-radiopharma.com)



## Lantheus - Program Partner

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit:

[www.lantheus.com](http://www.lantheus.com)



## Mirion Medical - Program Partner

Mirion Medical, a global leader in radiation safety solutions, enables the development and deployment of the latest generation of precision diagnostic and therapeutic radiopharmaceuticals through a proven portfolio of trusted brands, including market leaders Capintec and ec<sup>2</sup> Software. Our interconnected ecosystem combines hardware and software to support every stage of the radiopharmaceutical lifecycle, from isotope creation to patient delivery, providing end-to-end transparency for pharmaceutical owners, and ensuring safety and product quality at every step.

[www.mirion.com/radiopharma](http://www.mirion.com/radiopharma)

REGISTER  
BY JULY 28 &  
SAVE \$100

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW

21

+1 617 455 4188

@ [info@hansonwade.com](mailto:info@hansonwade.com)

[www.targeted-radiopharma-us.com](http://www.targeted-radiopharma-us.com)

[Targeted Radiopharmaceuticals](#)



# Proud to Partner With

4th Annual **TRP** Targeted Radiopharmaceuticals Summit US  
July 29-31, 2025 | San Diego, CA



## PepLib - Program Partner

PepLib is a biotech company specializing in peptide drug discovery, leveraging its cutting-edge platform that includes PICT, disulfide-rich peptide phage display, and a machine learning-driven in silico design platform to accelerate the discovery of peptides with high affinity and specificity. PepLib's pipeline features over 30 innovative peptide radioligands targeting tumor-specific markers such as FAP, GPC3, Trop2, and DLL3. With a flexible partnership model, PepLib actively seeks collaborations or opportunities to out-license its therapeutic assets.

[www.peplib.com](http://www.peplib.com)



## PharmaLogic - Program Partner

PharmaLogic is a world-class contract development and manufacturing organization specializing in novel diagnostic imaging and therapeutic radiopharmaceuticals for the treatment of cancers and other diseases. PharmaLogic has decades of expertise in drug development from discovery to commercialization through atop-tier network of radiopharmacies in North America. The Company seeks to take the lead in the advancement of radiopharmaceutical technology for the benefit of patients worldwide. For more information, visit:

[www.radiopharmacy.com](http://www.radiopharmacy.com)



## PPD, Thermo Fisher Scientific - Hosting Partner

Thermo Fisher is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. The PPD clinical research business of Thermo Fisher Scientific enables customers to accelerate innovation and increase drug development productivity.

Thermo Fisher Scientific supplies innovative solutions for the world's pharmaceutical and biopharmaceutical industries. With applications that span the drug development process – from drug discovery through large-scale commercial production – utilizing patient -centered strategies and data analytics, our capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel approaches to patient recruitment and investigator sites, and comprehensive laboratory services.

Recognized as a global industry leader in accelerating promising medicines from early development through regulatory approval and market access, we serve pharma, biotech, medical device and government organizations with custom tailored solutions, including full-service partnerships and functional service partnerships. As a strategic partner in clinical development and analytical services, we apply cutting edge technologies, therapeutic expertise and a firm commitment to quality, to help customers deliver life -changing therapies.

[www.ppd.com/therapeutic-expertise/oncology-and-hematology-cro/radiopharmaceutical-therapy/](http://www.ppd.com/therapeutic-expertise/oncology-and-hematology-cro/radiopharmaceutical-therapy/)



## TerThera - Hosting Partner

TerThera is a radionuclide production company headquartered in the Netherlands, dedicated to advancing the field of nuclear medicine. The founders and team members of TerThera bring decades of experience within the nuclear medicine industry and are fully committed to the production of the innovative radionuclide Terbium-161 (Tb-161). The company is actively establishing a global platform to address the increasing demand for radionuclides in oncology and nuclear medicine and will be offering its product as GMP shortly.

[www.terthera.com](http://www.terthera.com)

REGISTER  
BY JULY 28 &  
SAVE \$100

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW



+1 617 455 4188

@ [info@hansonwade.com](mailto:info@hansonwade.com)

🌐 [www.targeted-radiopharma-us.com](http://www.targeted-radiopharma-us.com)

in Targeted Radiopharmaceuticals





# Proud to Partner With



## Modular Devices- Hosting Partner

Modular Devices Cleanrooms engineers and manufactures modular cleanrooms that meet the strict standards for radiopharmaceuticals and biotech while delivering the flexibility necessary for small-batch and decentralized manufacturing. Our pre-built and customized solutions meet cGMP, USP <825>, and ISO standards, supporting safe and compliant research, development, and production environments. With rapid deployment, flexible configurations, and expert support, we enable clients to accelerate time to delivery while maintaining strict quality control. Learn more:

[www.modulardevices.com](http://www.modulardevices.com)



## Stream Realty Partners - Hosting Partner

Stream Realty Partners is a national commercial real estate firm offering an integrated platform of leasing, investment and development services. This includes tenant and landlord representation, Legendary CX property management, capital markets, investment management and sales, construction, construction management, national program management, workplace strategies, strategic marketing, and dedicated research. The company is headquartered in Dallas with operations in core markets coast to coast. Since 1996, Stream has grown to more than 1,550 professionals and now completes annual transactions valued at more than \$8.9 billion in office, industrial, retail, healthcare, land, and data center properties. For information, visit [www.streamrealty.com](http://www.streamrealty.com) and follow Stream on LinkedIn, Instagram, X and Facebook.

[www.streamrealty.com](http://www.streamrealty.com)



LigandTracer

## Ridgeview Instruments - Panel Partner

Ridgeview Instruments provides the instrument family LigandTracer® for easy affinity characterization of radio/pharmaceuticals with their target receptor. An appropriate in-situ target environment is ensured by enabling measurements on cells, tissue (fresh/fixed) or organs.

With real-time interaction analysis, LigandTracer provides robust determination of affinity and avidity through kinetic binding rate constants, while also offering insights into binding stability and molecular recognition. LigandTracer is plug and play with few preparatory steps and limited hands-on time.

[www.ligandtracer.com](http://www.ligandtracer.com)



## Trasis - Innovation Partner

At Trasis, we are committed to helping the nuclear medicine community access new radio-labelled therapeutic and diagnostic substances more easily and efficiently. Since the company's founding in 2004, Gauthier Philippart, our CEO, has driven long-term market strategy, while Jean-Luc Morelle, our CTO, has led technological innovation. Our proven radiopharmaceutical expertise, combined with high-end instruments, enables us to provide fully integrated solutions for efficient tracer production and a faster transition from drug development to marketing authorization.

[www.trasis.com](http://www.trasis.com)



## SHINE - Innovation Partner

Based in Janesville, Wisconsin, SHINE specializes in the production of n.c.a. Lu-177 and other medical isotopes. Through innovative fusion technology, SHINE is advancing cancer treatment and diagnostics while exploring applications in healthcare and sustainable energy. Learn more at:

[www.shinefusion.com](http://www.shinefusion.com)

REGISTER  
BY JULY 28 &  
SAVE \$100

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW

# Proud to Partner With

4th Annual **TRP** Targeted Radiopharmaceuticals Summit US  
July 29-31, 2025 | San Diego, CA



## Flywheel - Innovation Partner

Flywheel is the platform for global medical imaging data management and AI development. It thrives on identifying cohorts, curating data, and training models to nurture trusted AI. Flywheel empowers a world where each insight from medical imaging is informed, precise, and impactful, harnessing the potential of imaging data for trustworthy AI. Flywheel, better data for better AI.

[www.flywheel.io](http://www.flywheel.io)



## Perceptive - Exhibition Partner

At Perceptive, we empower pharmaceutical, biotech, and clinical research organizations to rapidly discover and advance life-changing medicines by delivering unmatched scientific and technological expertise, global operational experience, and end-to-end solutions that ensure confident R&D decision-making. But we are not in the business of clinical research. We are in the business of time and reassurance. In our world, time is more valuable than money. Time is lives. Where dependability and reliability are fundamental, we deliver reassurance at the speed of life

[www.macrocyclics.com](http://www.macrocyclics.com)



## IONETIX - Exhibition Partner

IONETIX is a full-service, end-to-end radiopharmaceutical solutions provider. Utilizing a proprietary cyclotron technology platform, Ionetix develops innovative accelerator solutions to produce medical radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals. Ionetix is currently in the process of establishing the first commercial alpha isotope manufacturing and distribution facility dedicated to the production of Actinium-225 (Ac- 225) and Astatine-211 (At- 211). Ionetix will provide isotope production, drug manufacturing and distribution logistics for these alpha isotopes beginning in early 2023.

<https://www.ionetix.com/alpha-therapy/>



## Isotopia Molecular Imaging - Exhibition Partner

Isotopia Molecular Imaging is an Israel-based global pharmaceutical and nuclear medicine manufacturing company with proven expertise in developing, manufacturing, and commercializing pioneering diagnostic and therapeutic products. Established in 2007, Isotopia is finishing the buildout of its U.S. headquarters and state-of-the-art manufacturing facility in Indianapolis, Indiana. The company plans to begin production of GMP-grade Lu-177 n.c.a. – a radioactive medical isotope used in pharmaceuticals for cancer treatment – for delivery to its customers by the end of 2024.

[www.isotopia-global.com](http://www.isotopia-global.com)



## Macrocytics - Exhibition Partner

Macrocytics, Inc., founded in 1995 and headquartered in Plano, Texas, is a CDMO specializing in chelating agents for radiopharmaceuticals and nuclear medicine. A subsidiary of Orano Med, the company provides custom synthesis, kilo-scale manufacturing, and bioconjugation services to accelerate early-stage pharmaceutical development. Macrocytics also offers CMC analytical services, maintains a GMP compliant Quality System, and stocks a catalog of over 90 products available online. With a dedicated team of project managers, the company ensures end-to-end project support while delivering innovative solutions to overcome complex challenges.

[www.macrocyclics.com](http://www.macrocyclics.com)

REGISTER  
BY JULY 28 &  
SAVE \$100

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



REGISTER  
NOW





# Proud to Partner With

4th Annual **TRP** Targeted Radiopharmaceuticals Summit US  
July 29-31, 2025 | San Diego, CA



## AtomVie - Event Partner

AtomVie Global Radiopharma (AtomVie) is a leading global CDMO specializing in GMP-compliant manufacturing and distribution of radiopharmaceuticals. AtomVie provides a comprehensive range of scientific, technical, regulatory, quality, and logistics expertise to support the development of your radiopharmaceuticals from Phase 1 to market. AtomVie is constructing a state-of-the-art, purpose-built, and scalable 72,300 sq. ft. cGMP facility, which will be ready by the end of 2025 for clinical and commercial-scale production of radiopharmaceuticals

[www.atomvie.com](http://www.atomvie.com)



## NorthStar - Event Partner

NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar's expanding industry-leading position in the emerging field of radiopharmaceutical therapy is supported by its unique capabilities in the sophisticated production of radioisotopes, proven management team, and state-of-the-art, environmentally preferable technologies. NorthStar routinely produces copper-67 (Cu-67) and is poised to be the first commercial-scale producer of non-carrier added actinium-225 (n.c.a. Ac-225). The Company's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs.

[www.northstarm.com](http://www.northstarm.com)



## PeptiFinder - Exhibition Partner

PeptiFinder Biotech is the pioneering CRO specializing in mRNA display technology. At PeptiFinder, we leverage a superior mRNA display platform featuring a variety of libraries (linear, monocyclic and bicyclic peptides) with ultra-high-diversity (up to 10<sup>15</sup>) which can be screened against nearly any biological target of interest rapidly (6-8 weeks) with a remarkable success rate of over 95%. By incorporating unnatural amino acids into cyclic peptide libraries, we can generate peptides with enhanced physiochemical properties and optimized pharmacokinetics. Additionally, we offer custom library designs tailored to specific client needs.

[www.peptifinder.com/](http://www.peptifinder.com/)



## 48Hour Discovery - Event Partner

48Hour Discovery is a biotechnology company revolutionizing peptide drug discovery through its proprietary phage display platform. Leveraging cutting-edge technology, 48HD rapidly identifies, validates, and optimizes preclinical drug candidates providing an efficient and innovative solution for early-stage drug development. Since its founding in 2017, 48HD has partnered with over 25 companies, including global pharmaceutical leaders, to advance precision medicine and targeted therapies. Ask us about our growing portfolio of potent binders targeting high-value TRP assets.

[www.48hourdiscovery.com](http://www.48hourdiscovery.com)

**REGISTER  
BY JULY 28 &  
SAVE \$100**

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS



**REGISTER  
NOW**

25

+1 617 455 4188

@ [info@hansonwade.com](mailto:info@hansonwade.com)

[www.targeted-radiopharma-us.com](http://www.targeted-radiopharma-us.com)

[Targeted Radiopharmaceuticals](#)



# Partner With Us

## Your Global Platform to Foster New & Existing Relationships Within the Rapidly Expanding Radiopharmaceuticals Field

As more radiopharmaceutical developers move closer to approval, we are seeing a surge of new companies entering the field. With investment at an all-time high, these drug developers now require more isotope supply, CDMO services, high-quality couriers, preclinical CRO expertise, clinical CRO capabilities, imaging and radiation equipment than ever before. The **4th Targeted Radiopharmaceuticals Summit US** is the largest industry-focused platform where strategic industry leaders come to connect with the companies providing these essential services and solutions.

### Why Partner?



**Elevate your brand** within the busy landscape, distinguish yourself from the crowd and build trust with your industry to become the go-to radiopharmaceutical service provider to advance drug development



**Generate commercial opportunities** and meet distinguished radiopharmaceutical leaders or rising stars who are looking for cutting-edge technologies and services to progress their pipeline



**Uncover crucial market trends** to guide your business strategies in this growing arena



**Showcase your technical know-how** to key decision-makers when competition is high and engage in productive conversation

## Get Involved




**Mehmet Gul**

Partnerships Director

Tel: +1 617 455 4188


Email: [sponsor@hansonwade.com](mailto:sponsor@hansonwade.com)

### Type of Companies Attending\*



Biopharma  
Academic & Clinicians  
Diagnostics  
Investment  
Consultant  
Solution/Technology Provider  
Other

### Geo of Companies Attending\*



### Seniority of Attendees\*



67% - CXO, VP, Director/Head

28% - Manager, Professor, Project Leader

5% - Other

\*Stats taken from 3rd TRP US 2024

26

+1 617 455 4188

[info@hansonwade.com](mailto:info@hansonwade.com)

[www.targeted-radiopharma-us.com](http://www.targeted-radiopharma-us.com)

[Targeted Radiopharmaceuticals](#)



REGISTER  
BY JULY 28 &  
SAVE \$100

WELCOME

WHAT'S NEW  
FOR 2025?

SPEAKERS

AGENDA AT A  
GLANCE

PRE-  
CONFERENCE  
WORKSHOP  
DAY

CONFERENCE  
DAY ONE

CONFERENCE  
DAY TWO

PARTNER  
WITH US

PARTNERS




REGISTER  
NOW



# Ready to Register?

## 3 Easy Ways To Book

 <https://targeted-radiopharma-us.com/take-part/register/>

 Tel: +1 617 455 4188

 Email: [info@hansonwade.com](mailto:info@hansonwade.com)

## Team Discounts\*\*

- 10% discount – 3+ Attendees
- 15% discount – 4+ Attendees
- 20% discount – 5+ Attendees

\*\*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.  
Contact: [register@hansonwade.com](mailto:register@hansonwade.com)

- 1 Discover** what’s on the forefront of radiopharmaceutical innovation with key industry members pioneering the field, from moving the needle in clinical research to solving supply chain challenges.
- 2 Deliver** more drugs to the lives of patients in need. From continuing development across mature development and optimizing capabilities to exploring new directions in the field to find new targets across more indications.

Industry Pricing ***	Register, & Pay by July 28	On the Door Price
Conference + Workshop Day	\$4,197 (Save \$100)	\$4,297
Conference + Focus Day	\$4,197 (Save \$100)	\$4,297
Conference Only	\$2,999 (Save \$100)	\$3,099

Academic Pricing****	Register, & Pay by July 28	On the Door Price
Conference + Workshop Day	\$3,597 (Save \$100)	\$3,697
Conference + Focus Day	\$3,597 (Save \$100)	\$3,697
Conference Only	\$2,599 (Save \$100)	\$2,699

Service Provider Pricing	Register, & Pay by July 28	On the Door Price
Conference + Workshop Day	\$5,097 (Save \$100)	\$5,197
Conference + Focus Day	\$5,097 (Save \$100)	\$5,197
Conference Only	\$3,699 (Save \$100)	\$3,799

\*\*\*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email [info@hansonwade.com](mailto:info@hansonwade.com)

Do you work for a Not-for-Profit organization? Email us at [info@hansonwade.com](mailto:info@hansonwade.com) to inquire about attending

\*\*\*\*To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email [info@hansonwade.com](mailto:info@hansonwade.com)

Terms & Conditions

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

Venue

Hyatt Regency La Jolla

3777 La Jolla Village Drive, San Diego, CA 92122, United States

[www.hyattregencylajolla.com](http://www.hyattregencylajolla.com)



REGISTER BY JULY 28 & SAVE \$100

WELCOME

WHAT'S NEW FOR 2025?

SPEAKERS

AGENDA AT A GLANCE

PRE-CONFERENCE WORKSHOP DAY

CONFERENCE DAY ONE

CONFERENCE DAY TWO

PARTNER WITH US

PARTNERS

 REGISTER NOW